JP2019514347A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514347A5
JP2019514347A5 JP2018546004A JP2018546004A JP2019514347A5 JP 2019514347 A5 JP2019514347 A5 JP 2019514347A5 JP 2018546004 A JP2018546004 A JP 2018546004A JP 2018546004 A JP2018546004 A JP 2018546004A JP 2019514347 A5 JP2019514347 A5 JP 2019514347A5
Authority
JP
Japan
Prior art keywords
antibody
trem1
hvr
isolated antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018546004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514347A (ja
JP7023853B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/020745 external-priority patent/WO2017152102A2/en
Publication of JP2019514347A publication Critical patent/JP2019514347A/ja
Publication of JP2019514347A5 publication Critical patent/JP2019514347A5/ja
Priority to JP2022018475A priority Critical patent/JP7480197B2/ja
Application granted granted Critical
Publication of JP7023853B2 publication Critical patent/JP7023853B2/ja
Priority to JP2024070972A priority patent/JP2024119791A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018546004A 2016-03-04 2017-03-03 抗trem1抗体及びその使用方法 Active JP7023853B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022018475A JP7480197B2 (ja) 2016-03-04 2022-02-09 抗trem1抗体及びその使用方法
JP2024070972A JP2024119791A (ja) 2016-03-04 2024-04-24 抗trem1抗体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662304018P 2016-03-04 2016-03-04
US62/304,018 2016-03-04
PCT/US2017/020745 WO2017152102A2 (en) 2016-03-04 2017-03-03 Anti-trem1 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022018475A Division JP7480197B2 (ja) 2016-03-04 2022-02-09 抗trem1抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2019514347A JP2019514347A (ja) 2019-06-06
JP2019514347A5 true JP2019514347A5 (enExample) 2020-04-16
JP7023853B2 JP7023853B2 (ja) 2022-02-22

Family

ID=58348000

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018546004A Active JP7023853B2 (ja) 2016-03-04 2017-03-03 抗trem1抗体及びその使用方法
JP2022018475A Active JP7480197B2 (ja) 2016-03-04 2022-02-09 抗trem1抗体及びその使用方法
JP2024070972A Withdrawn JP2024119791A (ja) 2016-03-04 2024-04-24 抗trem1抗体及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022018475A Active JP7480197B2 (ja) 2016-03-04 2022-02-09 抗trem1抗体及びその使用方法
JP2024070972A Withdrawn JP2024119791A (ja) 2016-03-04 2024-04-24 抗trem1抗体及びその使用方法

Country Status (4)

Country Link
US (3) US11472877B2 (enExample)
EP (1) EP3423493A2 (enExample)
JP (3) JP7023853B2 (enExample)
WO (1) WO2017152102A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) * 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
EP3664845A4 (en) * 2017-08-08 2021-03-10 Pionyr Immunotherapeutics, Inc. COMPOSITIONS AND METHODS FOR DEACTIVATING MEYLOID CELLS EXPRESSING TREM1
US11746150B2 (en) 2017-12-19 2023-09-05 Surrozen Operating, Inc. Anti-LRP5/6 antibodies and methods of use
CA3085596A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-frizzled antibodies and methods of use
US11975024B2 (en) 2017-12-19 2024-05-07 Musc Foundation For Research Development T regulatory (Treg) cell transplantation in osteogenesis imperfecta (OI)
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
CN111886246B (zh) * 2017-12-29 2024-12-17 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
MX394121B (es) 2018-03-14 2025-03-24 Surface Oncology Inc Anticuerpos que se unen a cd39 y sus usos
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
KR20210060477A (ko) 2018-09-17 2021-05-26 압큐로, 인크. 항-klrg1 항체
CN113039205B (zh) * 2018-10-26 2024-03-22 科济生物医药(上海)有限公司 靶向cll1的抗体及其应用
AU2020218525A1 (en) * 2019-02-06 2021-09-23 Pionyr Immunotherapeutics, Inc. Anti-TREM1 antibodies and related methods
US10836828B2 (en) 2019-02-06 2020-11-17 Pionyr Immunotherapeutics, Inc. Anti-TREM1 antibodies and related methods
CN110170053A (zh) * 2019-05-30 2019-08-27 澳门科技大学 组合物、其在制备肿瘤免疫治疗药物中的应用及药物组合物
JP2022540904A (ja) * 2019-07-15 2022-09-20 ブリストル-マイヤーズ スクイブ カンパニー ヒトtrem-1に対する抗体およびその使用
WO2021011678A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
JP2022548484A (ja) 2019-09-16 2022-11-21 サーフィス オンコロジー インコーポレイテッド 抗cd39抗体の組成物及び方法
TW202216743A (zh) * 2020-06-26 2022-05-01 美商安進公司 Il-10突變蛋白及其融合蛋白
CA3197465A1 (en) 2020-11-02 2022-05-05 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
CN117642428A (zh) 2021-05-03 2024-03-01 Ucb生物制药有限责任公司 抗体
WO2022253991A1 (en) * 2021-06-02 2022-12-08 Inotrem Anti-trem-1 antibodies
JP2024527514A (ja) * 2021-06-25 2024-07-25 アムジエン・インコーポレーテツド Trem-1抗原結合タンパク質での循環器疾患の治療
CN120958031A (zh) 2023-04-21 2025-11-14 赛斯尔斯治疗公司 抗trem1抗体药剂、组合物及其用途

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク. 免疫したゼノマウス(XenoMouse)に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
JP2006504971A (ja) 2002-11-01 2006-02-09 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド,ア・ボディー・コーポレイト マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
KR20070107687A (ko) 2004-12-31 2007-11-07 제넨테크, 인크. Br3과 결합하는 폴리펩티드, 및 그의 용도
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2010132370A2 (en) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Soluble tlt-1 for the treatment and diagnosis of sepsis
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
WO2011047097A2 (en) 2009-10-13 2011-04-21 Sigalov Alexander B Inhibition of trem receptor signaling with peptide variants
WO2012009568A2 (en) 2010-07-16 2012-01-19 Adimab, Llc Antibody libraries
PL2814844T3 (pl) 2012-02-15 2017-12-29 Novo Nordisk A/S Przeciwciała wiążące i blokujące receptor aktywujący wykazujący ekspresję na komórkach szpikowych -1 (trem-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
ES2797625T3 (es) 2012-09-07 2020-12-03 Inst Nat Sante Rech Med Péptidos inhibitorios derivados del receptor desencadenante expresado en células mieloides-1 (TREM-1) y del transcrito similar a TREM 1 (TLT-1) y sus usos
AP2015008584A0 (en) * 2013-02-08 2015-07-31 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
KR20250110365A (ko) 2014-07-17 2025-07-18 노보 노르디스크 에이/에스 점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
PE20200486A1 (es) * 2017-08-03 2020-03-03 Alector Llc Anticuerpos anti-cd33 y metodos para utilizarlos

Similar Documents

Publication Publication Date Title
JP2019514347A5 (enExample)
JP2024119791A5 (enExample)
JP7132232B2 (ja) Cd137及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
US11104745B2 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
JP2018525999A5 (enExample)
JPWO2019226973A5 (enExample)
JP2020528752A5 (enExample)
JP2020500540A5 (enExample)
JP2019500014A5 (enExample)
JP2019500892A5 (enExample)
HRP20211980T1 (hr) Protutijela protiv sortilina i postupci njihove upotrebe
JP2018517401A5 (enExample)
EP3892634A1 (en) Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof
EA038349B1 (ru) Антитела, содержащие модифицированные константные участки тяжелой цепи
JP2020511947A5 (enExample)
JP2018516537A5 (enExample)
US20230365641A1 (en) Targeted cytokines and methods of use thereof
JP2020523038A5 (enExample)
CA3064298A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
JP2022540620A (ja) 胸腺間質性リンパ球新生因子(tslp)受容体シグナル伝達に干渉する薬剤
KR20250039361A (ko) 담체로서의 조작된 절단성 Fc 도메인 및 이의 사용 방법
TW202529810A (zh) 用於治療噬血球性淋巴組織細胞增生症之sirp抗體
JP7745556B2 (ja) Cd137結合分子及びその使用
TW202220691A (zh) 用於使用PD—1xCTLA—4雙特異性分子的方法
WO2025226685A1 (en) Sirp alpha, beta, gamma antibodies for treatment of epstein–barr virus infections